Factors associated with human papillomavirus vaccination among young adult women in the United States
Introduction
Genital human papillomavirus (HPV) is the most common sexually transmitted infection in the United States and can cause cervical cancer, genital warts and other anogenital cancers. Quadrivalent and bivalent HPV vaccines were licensed for use in the United States in 2006 and 2009, respectively, and recommended for prevention of vaccine HPV-type-related cervical cancers and cancer precursors [1], [2]. Routine HPV vaccination of females age 11 or 12 years is recommended [2] and vaccination of females age 13–26 years who have not been previously vaccinated [1], [2]. Routine cervical cancer screening is generally recommended at age 21 to age 65 years for adult women, regardless of HPV vaccination status, although guidelines may differ from one another with regards to when to start, stop, how often to screen, and use of the conventional Pap test or liquid-based cytology [1], [3], [4], [5], [6].
Since HPV vaccine was recommended for use in females, estimates of vaccine coverage among young women have been published [7], [8], [9], [10], [11], [12]. In previous reports factors associated with HPV vaccination in adult women (≥18) have included white race, higher education and income, having insurance, discussions with a healthcare provider about HPV vaccine, history of sexual activity, and receipt of other vaccines [7], [8], [9], [10], [11]. Concern about vaccine safety, doctors not recommending vaccination and cost have been barriers to HPV vaccination [8], [12].
This study at four years following first licensure of HPV vaccine uses national data to update information among age-eligible adult women on associations of initiation and receipt of the complete three dose series.
Section snippets
Methods
We analyzed data from the 2010 National Health Interview Survey (NHIS) which collected data throughout the year using a design oversampling for Hispanics, blacks, and Asians to produce nationally representative samples. The 2010 NHIS sample adult core included questions about HPV infection, Pap testing, and HPV vaccination. The NHIS protocol was approved by the National Center for Health Statistics Research Ethics Review Board (ERB # 2009-16). Additional details about the 2010 NHIS are located
Ever told had HPV, cervical cancer screening and awareness of HPV vaccine
Overall, women age 27–30 years were more likely to have been told they had HPV (12.3%) than were women age 18–26 years (8.5%) (p < 0.05). These women were more likely to have ever heard of HPV vaccine (91.4%) and to have received at least one dose of HPV vaccine (30.2%) than women who had not been told they had HPV (84.7% and 19.9%, respectively) (p < 0.05). Women age 18–26 and 27–30 years had similar likelihood of awareness of HPV vaccine (Table 1).
Among respondents age 18–20 years, 21–26 years,
Discussion
The findings of this study indicate that 4 years following the recommendation for routine vaccination at age 11 or 12 years and through age 26 for those not previously vaccinated, HPV vaccination remains low with initiation highest among women age 18–20 years. The finding of higher initiation levels at younger ages has been reported [8], [9], [11], [14] and might reflect the knowledge, attitude and practices of the healthcare providers of young adult women [9], the social norms of young women
References (42)
- et al.
Human papillomavirus (HPV) awareness and vaccination initiation among women in the United States, National Immunization Survey-Adult 2007
Prev Med
(2009) - et al.
Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey
J Adolesc Health
(2009) - et al.
Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007–2008
Prev Med
(2011) - et al.
Worsening disparities in HPV vaccine utilization among 19–26 year old women
Vaccine
(2011) - et al.
Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010
Vaccine
(2011) - et al.
Stage of adoption of the human papillomavirus vaccine among college women
Prev Med
(2009) - et al.
Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system
Vaccine
(2010) - et al.
Predictors of HPV vaccine uptake among women age 19–26: importance of a physician's recommendation
Vaccine
(2011) - et al.
Influenza and pneumococcal vaccination of adults age ≥65: racial/ethnic differences
Am J Prev Med
(2005) - et al.
The role of attitudes in understanding disparities in adult influenza vaccination
Am J Prev Med
(2006)